Bayer

Bayer

  • July 2020 •
  • 46 pages •
  • Report ID: 5955605 •
  • Format: PDF
PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Bayer’s prescription drug sales will experience modest growth over the forecast period.
Key themes – [1] Xarelto and Eylea, Bayer’s two flagship drugs, will see robust global growth in the short term [2] Growth in China is key for several of Bayer’s franchises [3] Genitourinary remains a key therapy area, as Mirena will drive sales growth.

Model updates (26 April 2020)

Xarelto forecast adjusted higher due to higher volumes globally and stable performance in the US
Glucobay forecast adjusted lower due to COVID-19 impact in China
Jivi forecast removed due to Bayer consolidating Jivi sales with Kogenate.

Model updates (26 February 2020)

Eylea forecast adjusted higher due to continued strength in Europe, Japan, and the Middle East
Betaferon/Betaseron forecast adjusted lower due to continued market share losses in the US.

Model updates (30 October 2019)

Eylea forecast adjusted higher due to continued strength in Europe, Japan, and Middle East
Yaz/Yasmin/Yasminelle forecast adjusted higher
Betaferon/Betaseron forecast adjusted lower due to continued market share losses in US.

Model updates (9 August 2019)

Xarelto forecast adjusted lower in the US due to lower licensing revenues from Johnson and Johnson, and higher in Europe and RoW, driven by expanded volumes in China, Russia, and France
Eylea forecast adjusted higher due to strength in Europe, Japan, and Canada
Nexavar sales adjusted higher in China and lower in the US and Japan
Stivarga forecast adjusted higher due to expanded volumes in China and Russia
Aliqopa forecast adjusted lower due to 5EU and RoW launches being pushed out
Vericiguat forecast added
Nubeqa forecast added
Molidustat forecast added
Finerenone forecast added
Vericiguat forecast added
Other revenue adjusted lower due to sale of Animal Health division to Elanco.